Linear expands commercialisation of Orchid SRV device
Medical device company Linear Health Sciences has announced expanded commercialisation of its Orchid SRV tension-activated breakaway safety release valve, via an agreement with Health Care Technology (HCT) covering distribution in, New York, Pennsylvania, West Virginia, Delaware, Maryland, Washington, D.C., and Virginia; and an agreement with McArthur Medical covering all of Canada.
Dislodgement of IV catheters is a significant problem that often flies under the radar. More than 340 million peripheral IVs are administered in the U.S. each year; dislodgement and associated failure modes are estimated to cost the American healthcare system more than $340 million annually. The Orchid SRV, a sterile, single-use connector for needle-free access, makes return to treatment fast, simple, and clean, while improving both the patient and clinician experience.
Placed between the existing IV extension set and general IV tubing connection, when tension (of up to 3.25 lbs.) acts on the IV line, the valve separates and seals off both sides of the IV, creating a sterile barrier. The clinician then restores the line simply by removing the separated halves and replacing them with a new, pre-packaged, sterile valve.
Clinical simulation testing of 360 Orchid SRVs showed that the device prevented IV dislodgement by 91.1% across all test groups. The Orchid SRV is indicated for use during direct injection, intermittent infusion, and continuous infusion.
Adam Benson, CEO of HCT, said: “HCT is very excited to be partnering with Linear Health Sciences. Linear’s Orchid technology will drastically improve patient care related to IV infusion and safe IV therapy practice.”
“Our team of clinicians gets inspired when they see innovations like the Orchid from Linear Health Science,” added Frank Fiorenza, VP of sales and marketing at McArthur Medical, the Canadian distribution arm of Linear Health Sciences. “This is a product that will help staff manage workload and improve patient satisfaction.”
Dan Clark, co-founder and CEO of Linear Health Sciences, commented: “An important part of our mission is helping to raise awareness of the impact of IV dislodgment and the larger issue of premature catheter failure. In addition to expanding patient access to this ground-breaking safety technology, we expect these agreements to be instrumental in calling attention to this important patient safety issue and ultimately to help educate the market on a failure mode that is too often considered normal.”
Linear Health Sciences won an Innovative Technology Award for Orchid SRV from Vizient, and the device will be offered to hospital customers through a non-exclusive contract with the group purchasing organisation (GPO). Orchid SRV won a 2023 BIG Innovation Award from the Business Intelligence Group. Qualified clinical evaluations of Orchid SRV will continually quantify device utilization and drive Linear Health Science’s next generations of innovation.